Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rozin, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rozin, A.
Related Collections
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 1124-1125
© 2003 British Society for Rheumatology

Letters to the Editor

Infliximab efficiency in refractory Wegener's granulomatosis

A. Rozin

The B. Shine Department of Rheumatology, Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

The first 10% of the full text of this article appears below.

SIR, The long-term remission (6–24 months) of refractory Wegener's granulomatosis seen following 4–6 infusions of infliximab (anti-TNF) therapy [1] compelled us to consider the following explanations. After an initial phase of therapy at 0-, 2- and 4-week intervals, infliximab is usually given every 8 weeks in order to prevent a decrease . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?